Objective:

To highlight the delays in patient diagnosis that hinder access to precision therapies, despite significant advancements in drug development, including targeted therapies and personalized medicine.

Key Findings:

• Diagnosis delays can extend to several years, particularly for rare diseases, significantly impacting treatment outcomes.
• Current commercial models primarily target physicians, neglecting the patient journey prior to diagnosis, which can lead to lost opportunities for early intervention.
• Precision medicine requires a shift in focus to recognize and address patient needs earlier in the diagnostic process, emphasizing the urgency of timely diagnosis.

Interpretation:

The disconnect between drug development and patient diagnosis represents a significant barrier to effective treatment, particularly in precision medicine, leading to delayed access to potentially life-saving therapies.

Limitations:

• The article does not provide specific data on the effectiveness of proposed solutions, which limits the ability to assess their potential impact.
• It lacks detailed case studies illustrating successful integration of commercial and clinical strategies, which could provide valuable insights.

Conclusion:

Addressing the last mile problem in diagnosis is crucial for ensuring that precision therapies reach the patients who need them most, necessitating a reevaluation of commercial strategies in biopharma to include insights from patient journeys.